Swixx BioPharma is designed to fully replace biopharma, OTC and medical device multinationals’ subsidiaries or business units in those countries, or therapeutic areas of CEE, that the multinational chooses not to enter, or to exit.With 500+ employees and sales likely to top 230 million Euros in 2020, Swixx BioPharma is already the largest agent for ethical pharmaceuticals serving research-based biopharma in CEE. The company is staffed by a unique group of access-savvy managers and medical professionals who are dedicated to bring modern medicines to the people of CEE region. We are a service-oriented, high quality and ethically-driven company.
Swixx BioPharma began operations in December 2014 and is registered in Baar, Switzerland. The company has 100%-owned affiliates in Albania, Bosnia & Herzegovina, Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Kosovo, Latvia, Lithuania, North Macedonia, Montenegro, Poland, Romania, Serbia, Slovakia and Slovenia. Both Swixx BioPharma senior management and owners come from a heritage of unique success in specialty pharmaceuticals in the CEE region. Swixx BioPharma enjoys strong financial connections with banks, hedge funds and private equity – should the need or opportunity arise, we have unsurpassed ability to raise capital quickly and efficiently
Baar, Switzerland – Swixx BioPharma AG of Baar, Switzerland announced today the signing of a distribution agreement with Amryt Pharma Plc (“Amryt”) through its wholly owned subsidiary Aegerion Pharmaceuticals Limited. Under the agreement, Amryt has appointed Swixx as exclusive distributor of Myalepta® (metreleptin) in the EU territories of Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Slovakia, Slovenia. In addition, Swixx will distribute Myalepta® for Amryt in the West Balkan countries of Albania, Bosnia and Herzegovina, Kosovo, Montenegro, North Macedonia and Serbia.
Myalepta® has been approved by the EMA as a treatment, in conjunction with diet, to treat the complications of leptin deficiency in patients with generalized and partial lipodystrophy. “It’s both exciting and a privilege for me to announce that Amryt has selected Swixx to assist to bring this new therapy to both CEE patients and CEE healthcare providers” commented Swixx Rare Disease Business Unit Head and Chief Commercial Officer (COO), Dr. Dezso Martha. Metreleptin is an important and breakthrough therapy for treating lipodystrophy and is eagerly awaited by patients across CEE. There is a definite unmet need for new therapies to treat the complications of leptin deficiency in patients with congenital or acquired generalised lipodystrophy and in a subset of patients with partial lipodystrophy.
This deal represents a rare disease milestone for Swixx” enthused Swixx’s CEO, Jean-Michel Lespinasse. “We embarked on building a rare disease business unit at Swixx just a year ago; inking this deal with Amryt both diversifies our company’s portfolio and validates Swixx as a strategic partner in rare and ultra-rare diseases in CEE.
We thank our new colleagues at Amryt for affording Swixx this opportunity and we keenly anticipate working with lipodystrophy patients across the sixteen countries where Amryt has entrusted Swixx to distribute Myalepta